The purpose of this study was to further understand the mechanisms involved in ultrasoundmediated delivery of DNA (sonoporation); in particular, to understand how a plasmid should be formulated with an ultrasound contrast agent (UCA). Different polymer adjuvant-UCA combinations were formulated, and their impact on in vitro DNA transfection, was determined, under various experimental conditions. When present in the medium surrounding a cell suspension, and in the presence of a plasmid encoding for the green fluorescent protein (GFP), expression following sonoporation was increased by more than 1.5-fold compared to that achieved in control experiments (without the adjuvants). The effects of the adjuvants were not influenced by the nature of the UCA, nor that of the transfected cells; in contrast, the adjuvant concentrations, their physicochemical properties, and the manner in which they were used, did have an impact on transfection. Close association of the adjuvants to the UCA inhibited their action, suggesting that these substances must have access to the cell membrane to be effective. 2
Introduction
Ultrasound-mediated delivery of DNA (sonoporation) is a relatively new and promising method for gene therapy (1) (2) (3) (4) (5) . Compared to viral and non-viral transfection techniques, sonoporation introduces the genetic material into cells or tissues with high spatial and temporal specificity and control, and with minimal toxicity. However, the approach is yet to realize its full potential for a number of reasons: first, the mechanisms involved in sonoporation are not completely understood; second, the technology is complex; and third, the manner in which a plasmid should be formulated with an ultrasound contrast agent (UCA), i.e., gas-filled microbubbles or microcapsules, has not been investigated in terms of physico-chemical composition, in any detail whatsoever. These issues clearly need to be addressed and, to a certain extent, resolved, before a safe, effective and practical treatment can be evolved. This work contributes to the further elucidation of the mechanism(s) of sonoporation, and focuses on the impact of the UCA formulation (6) (7) (8) . In the present study, it was hypothesized that some biocompatible polymers used as pharmaceutical adjuvants in drug formulation such as polyethylene glycols (PEG) and amphiphilic molecules such as Pluronic®, Tween® and Triton X-100 could be useful for improving the efficacy of sonoporation since these polymers have been known for their capacity to increase the fluidity, permeability of cell membrane (9, 10) ; to preserve and repair against membrane damage (11) (12) (13) ; to facilitate drug and plasmid transport and to enhance gene transfer (14) (15) (16) (17) . Thus, the effect of polymer adjuvants (Pluronic F127, F68 and L61, PEG 4000 and PEG 35000) to the UCA on DNA transfection has been assessed under a range of experimental conditions (different cell types transfected, different adjuvants and UCA, and different incubation methods). The additional or synergistic effect of the adjuvant to UCA was evaluated with the efficacy of transfection (%cells positive to reporter protein GFP; and cell viability post sonoporation). The effect of polymeric adjuvants (PEG4000 and Pluronic® F127) on cell membrane fluidity was further assessed by measuring fluorescence anisotropy and compared with the results of the transfection.
Materials and Methods

Cell culture
Rat mammary carcinoma cells (MAT B III, CRL-1666, ATCC-LGC) were incubated at 37°C, in 225 cm 2 tissue culture flasks in a solution of MacCoy's 5A medium containing Glutamax (Life Technologie, Basel, Switzerland), and supplemented with 10% v/v foetal calf serum (FCS) and 1% v/v antibiotics (initial concentration: 10,000 IU/ml Penicillin, 10,000 μg/ml Streptomycin, 25 μg/ml Fungizone, Bioconcept, Alschwil, Switzerland) under a 5% CO 2 atmosphere.
Human embryonic kidney cells (HEK 293-H, 11631-017, GIBCO) were incubated at 37°C, 5% CO 2 atmosphere in 75 cm 2 tissue culture flasks in a DMEM medium supplemented with 10%
FCS and 1% non-essential amino acids, under a 5% CO 2 atmosphere. Prior to ultrasound exposure, 293-H cells were carefully detached from culture flasks using 0.05% trypsin solution containing 0.53mmol of EDTA. All cells were re-suspended in the culture medium without FCS for ultrasound exposure.
Ultrasound exposure
In a 3 ml polystyrene round-bottom tube, serving as ultrasound exposure chamber, 500 µl of cell suspension (1 x 10 6 cells/ml) were mixed with 5 µg of plasmid gWiz TM -GFP (Aldevron, Fargo, ND, USA) encoding for the green fluorescent protein (GFP) and an ultrasound contrast agent (UCA) consisting of 15 x 10 6 microcapsules (i.e., a particle-to-cell ratio of 30 capsules/cell). The UCAs used were air-filled microcapsules made of tripalmitine (BG1593 and BG1766, Bracco
Research SA, Geneva, Switzerland). The tube was held in a mechanically rotating system and immersed in a water bath thermostated at 37°C. The distance between the tube and the ultrasound transducer was 7.6 cm (optimized for a maximum ultrasound exposure). MAT B III cells were insonified at a peak negative pressure of 570 KPa for 10 seconds, using a focused 
Results
Different contrast agents, such as Definity ® (Bristol-Myers Squibb Canada, Inc., Saint-Laurent, Quebec) and Byk963 (Byk Gulden Lomberg Pharmaceuticals, Clinical Pharmacology, Konstanz, Germany), are formulated with adjuvant: the former contains a pegylated phospholipid (DPPE PEG 5000), while the latter has Pluronic ® F68 introduced during the microbubble preparation process (19) . BR14 (Bracco Research SA, Geneva, Switzerland), which has already been tested in sonoporation experiments, is also prepared in a solution of PEG 4000. As these adjuvants are commonly used in pharmaceutical applications, for example to stabilize formulations, their potential to enhance ultrasound-mediated gene delivery and/or improve cell viability post sonoporation, was considered a useful question to pursue.
Effect of "free" and "grafted" polymers on transfection
Air-filled BG 1766 microcapsules were used as control, and the presence of polyethylene glycol (PEG) 4000, Pluronic ® F68 or Pluronic ® F127 was subsequently evaluated. Figure 1 shows that all three polymers, when unassociated with the UCA ("free") in the cell suspension, enhanced transfection efficiency as measured by the % of GFP-positive cells (increase from 20% to 30%).
However, when Pluronic ® F127 was incorporated ("grafted") into the UCA during its preparation, transfection (% GFP-positive cells) was not different from the control value. With respect to the fluorescence intensity observed, no differences were found between the formulations.
Concentration and nature of adjuvant
Sonoporation experiments were performed using different adjuvants at different concentrations. 
Timing of adjuvant administration
To explore whether polymer adjuvants elicit their effects via an action on the plasmid (e.g., DNA stabilization) or on the cell membrane (e.g., fluidization), the manner in which PEG 4000 and Pluronic ® F127 were added to a MAT B III cell suspension before ultrasound exposure, was varied: (i) the adjuvant, UCA, and then the DNA were separately added to the cell suspension and the mixture was immediately insonified (denoted as "no incubation"); (ii) adjuvant was first incubated with the DNA solution for 20 minutes, then mixed with the cell suspension containing the UCA and insonified (denoted as "incubation with DNA"); (iii) the adjuvant was first incubated with the cell suspension for 20 minutes, then mixed with DNA and UCA, and finally insonified (denoted as "incubation with cells").
The control experiment utilized the BG1766 UCA together with 10 µg/ml of DNA but without adjuvant. Figure 4 shows that the transfection efficiencies with "no incubation" and with "incubation with DNA" for both PEG 4000 and PF 127 were similar and significantly better than the control (16% ± 1.4 compared to 22% ± 1.2 respectively). Transfection efficiency was significantly improved when the adjuvant molecules were first incubated with the cells to be transfected, and an increase of about 5% of GFP-positive cells was obtained. However, no significant differences were observed between the various preparations with respect to fluorescence intensity (data not shown).
In all these experiments, adjuvant was introduced before insonification of the cells.
Subsequently, the Pluronic ® was added to the cells after sonoporation; three conditions were compared: (a) without adjuvant (control); (b) after 1 hour incubation of PF 127 with the cells before sonoporation; and (c) addition of polymer to the cells after ultrasound exposure. Figure 5 indicates that, when polymer was added immediately after ultrasound exposure, transfection rate was decreased 2-fold (p = 0.000) and cell viability, relative to the other conditions, was reduced from approximately 70 to 50%. In contrast, when cells were pre-incubated with Pluronic ® F127, GFP expression rate reached 28% vs 20% for the control conditions.
Study of membrane fluidity of cells in the presence of adjuvants
The Figure 7A demonstrates that PEG 4000 at 0.02% w/v increased significantly transfection rate, but that further augmentation of the polymer concentration had no effect. Fluorescence anisotropy was not affected; on the other hand, as for Pluronic ® F127, and no plateau was observed for cell viability at high amounts of PEG 4000. In contrast to Pluronic ® F127, cell viability progressively increased with PEG 4000 concentration ( Figure 7B ).
Discussion
PEG has been extensively examined in biochemical and pharmaceutical applications, e.g., for membrane fusion (22), as a particle/membrane surface-modulating agent (23) and for membrane solubilization (24) . Pluronic ® (or Poloxamers) are known to enhance the permeation of hydrophobic molecules, such as doxorubicin, across cell membranes, to increase membrane fluidity (21) , and to facilitate gene transfer (25) . Equally, the action of both PEGs and Pluronic ® depend (inter alia) upon their hydrophilic-lipophilic balance and their concentration (21).
While our work was in progress (26), Chen and co-workers showed that ultrasound alone -i.e.
without contrast agent -and Pluronic® work synergistically in enhancing gene delivery.
However, they did not unravel the mechanism of action of the Pluronic molecules. Indeed, we showed positive effects of adjuvants, such as PEG 4000 and Pluronic ® F68 and F127, on transfection efficiency, particularly when the polymers were added "free" to a cell suspension At lower concentrations (0.0002-0.002% w/v), Pluronic ® L61 again resulted in cell viabilities of ~50-60% ( Figure 3B ), but eventually improved transfection rate to more than 25% ( Figure 3A) .
However, the amount of DNA internalized was not affected in the same way ( Figure 3C ), which makes it difficult to draw mechanistic conclusions. Also intriguing is the observation that fluorescence intensities in 293-H cells were 3-fold higher than in MAT B III cells; this would imply easier transfection and nuclear uptake in the former despite their longer population doubling time (>20 hours compared to 12 hours for MAT B III cells).
Pluronic ® enhanced gene transfer and cell viability even when added shortly before sonoporation (Figures 2 and 4) . Adsorption of the polymers at the plasma membrane may be very rapid, or the polymers might simply be effective at very low surface concentrations. A 20-minute incubation of Pluronic ® F127 with cells, in the absence of DNA, seemed to further improve transfection ( Figure 4 ). This implies that the adjuvant is not acting directly on DNA itself, but that there is a polymer effect on the cell membranes. Pre-incubation of the adjuvant with the cells before sonoporation would allow more surfactant molecules to adsorb onto and/or integrate into the cell membrane. Figure 5 supports this contention in that transfection was enhanced when the Pluronic ® was present during sonoporation, and was even more successful with pre-incubation.
The increase in cell viability with increasing Pluronic ® F127 concentration ( Figure 6 ) suggests that this adjuvant improves cell repair post-sonoporation. This is consistent with the observation that Poloxamer 188 (which is similar to Pluronic ® F68: HLB = 29 (28) improved tissue (and cell membrane) recovery in a dose-dependent way following electroporation (32) . Facilitated re sealing of membranes porated by electrical, thermal, or other forces, has been deduced as the mechanism of action of this (and other) non-ionic, polymer surfactants (33) . It was noted, however, that transfection rate reached a plateau at 0.05% w/v PF 127. This may be due to the polymer reaching its critical micelle concentration (34;35), at which no further "free" surfactant molecules are available for interaction with the cell membrane (34) . Alternatively, DNA might form a complex with the Pluronic ® micelles (36;37), and decrease its availability for transfection.
The mechanism of action of PEG 4000 in sonoporation is more difficult to understand. PEG can fuse lipid bilayers, enhance drug permeation into cells, and repair membranes which have been perturbed (21) . PEG has also been used to improve gene delivery by lipofection (39) . The polymer may promote membrane fusion by dehydrating lipid headgroups (40) . PEG and Pluronic ® polymers are quite different; the former is hydrophilic, the latter amphiphilic.
The mechanisms of action as adjuvants in DNA delivery may be quite distinct, therefore. The fluorescence anisotropy data indicate that Pluronic ® PF 127 increases membrane fluidity while PEG 4000 does not (Figures 6 and 7) . It may be that the concentration of PEG used was simply insufficient to provoke any effect; after all, much higher levels are needed to induce membrane fusion. Indeed no change in membrane anisotropy was noted across the whole range of PEG concentration tested whereas even slight amount of Pluronic 127 decreased anisotropy. This demonstrates that PEG and Pluronic may exert their protective action through separate mechanisms. It would be of high interest to combine both reagents to unveil potential synergetic effects.
Further speculation on a putative mechanism of action for PEG 4000 in sonoporation is inappropriate in the absence of further experiments designed to test specific hypotheses. Given the quite modest effects observed to-date, the value of a detailed and systematic investigation must be weighed against the pursuit of alternative strategies that provide much greater enhancement of gene delivery.
Conclusions
Polymeric adjuvants present in UCA can improve in vitro transfection and cell viability even at moderate concentrations (0.05-0.1% w/v). PEG 4000, and Pluronic ® F68, F127, enhanced GFPexpression more than 1.5-fold compared to the contrast agent alone. The adjuvant effect was indifferent to the UCA and cell type used, but strongly depended upon the nature of the polymer, the manner in which it was presented to the cells, and its concentration. The adjuvants were not effective when grafted to the UCA, suggesting that their adsorption onto, or integration into, the cell membrane was necessary for efficacy. Pluronic ® F127 appears to fluidize the cell membrane, facilitating transient pore formation and re-sealing. The mechanism of action of PEG, on the other hand, remains unclear. 
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